2. Antibody-drug Conjugate/ADC Related Apoptosis
  3. Antibody-Drug Conjugates (ADCs) Apoptosis TNF Receptor
  4. Brentuximab vedotin

Brentuximab vedotin (cAC10-vcMMAE) is an antibody-drug conjugate (ADC) comprising an anti-CD30 antibody and the cytotoxic agent Monomethyl auristatin E (MMAE). Brentuximab vedotin inhibits CD30-positive cells with an IC50 of 2.5 ng/mL. Brentuximab vedotin can be used for the research of relapsed and refractory Hodgkin lymphoma.

For research use only. We do not sell to patients.

Brentuximab vedotin Chemical Structure

Brentuximab vedotin Chemical Structure

CAS No. : 914088-09-8

Size Price Stock Quantity
1 mg USD 500 In-stock
5 mg USD 1250 Get quote
10 mg USD 2000 Get quote
50 mg   Get quote  
100 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Other Forms of Brentuximab vedotin:

Brentuximab vedotin Related Antibodies

Top Publications Citing Use of Products

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Brentuximab vedotin (cAC10-vcMMAE) is an antibody-drug conjugate (ADC) comprising an anti-CD30 antibody and the cytotoxic agent Monomethyl auristatin E (MMAE). Brentuximab vedotin inhibits CD30-positive cells with an IC50 of 2.5 ng/mL. Brentuximab vedotin can be used for the research of relapsed and refractory Hodgkin lymphoma[1][2].

IC50 & Target

IC50: 2.5 ng/mL (CD30)[2]
In Vitro

Brentuximab vedotin (cAC10-vcMMAE) (1 μg/mL; 96 h) shows cytotoxicity to CD30+ in Karpas 299 cells[2].
? Brentuximab vedotin (CAC10-VCMMAE) (1 μg/mL; 12, 24 and 48 h) selectively induces growth arrest in G2/M phase then lead to apoptotic cell ?death[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Brentuximab vedotin Related Antibodies

Cell Cytotoxicity Assay[2]

Cell Line: Karpas 299 cells
Concentration: 1 μg/mL
Incubation Time: 96 h
Result: Showed cytotoxicity to CD30+ Karpas 299 cells with an IC50 value of 2.5 ng/mL.

Cell Cycle Analysis[2]

Cell Line: L540 cells
Concentration: 1 μg/mL
Incubation Time: 12, 24, and 48 h
Result: Selectively induced growth arrest in G2/M phase to apoptotic cell death.
In Vivo

Brentuximab vedotin (cAC10-vcMMAE) (10-120 mg/kg; i.p. for 3 weeks) the maximum tolerated dose (MTD) is between 30 and 40 mg/kg[2].
? Brentuximab vedotin (cAC10-vcMMAE) (0.3, 1 mg/kg; flanks injection; every 4 days for a total of 4 doses 1 mg/kg) induces tumor CD30 regression[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: SCID mice[2]
Dosage: 10 to 120 mg/kg
Administration: Intravenous injection; 10 to 120 mg/kg; for 3 weeks
Result: Showed an maximum tolerated dose between 30 and 40 mg/kg.
Animal Model: SCID mice[2]
Dosage: 0.3 and 1 mg/kg
Administration: Flanks injection; 1 mg/kg every 4 days for a total of 4 doses; 0.3 mg/kg every 4 days for a total of 4 doses
Result: Induced complete and durable tumor regression, but 0.3 mg/kg provided lower therapy than 1 mg/kg dose.
Clinical Trial
CAS No.
Appearance

Solid

Color

White to off-white

SMILES

[Brentuximab vedotin]
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

4°C, sealed storage, away from moisture and light

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

Purity & Documentation

Purity: 98.00%

COA (231 KB)

Handling Instructions (2659 KB)
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Brentuximab vedotin Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Brentuximab vedotin914088-09-8Antibody-Drug Conjugates (ADCs)ApoptosisTNF ReceptorAntibody-Drug ConjugatesTumor Necrosis Factor ReceptorTNFRcAC10-vcMMAESGN-35antibody-drug conjugateT-cell lymphomacutaneous T-cell lymphomaInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Salutation

Applicant Name *

 

Email Address *

Phone Number *

 

Organization Name *

Department *

 

Requested quantity *

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Brentuximab vedotin
Cat. No.:
HY-P99107
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

Request for HNMR Report

We have received your request and will respond to you as soon as possible.